The Vulnerability to Schizophrenia Mainstream Research Paradigms and Phenomenological DirectionsSTANGHELLINI, Giovanni; FUSAR-POLI, Paolo.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 338-345, issn 1381-6128, 8 p.Article

Philosophical Issues in the Prodromal Phase of PsychosisBROOME, Matthew; FUSAR-POLI, Paolo.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 596-605, issn 1381-6128, 10 p.Article

Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosisFUSAR-POLI, Paolo.Journal of psychiatry & neuroscience. 2012, Vol 37, Num 2, pp 106-112, issn 1180-4882, 7 p.Article

Cannabis Abuse and Vulnerability to Psychosis: Targeting Preventive ServicesKOLLIAKOU, Anna; FUSAR-POLI, Paolo; ATAKAN, Zerrin et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 542-549, issn 1381-6128, 8 p.Article

Perspectives in Psychopharmacological NeuroimagingFUSAR-POLI, Paolo.Current pharmaceutical design (Print). 2009, Vol 15, Num 22, issn 1381-6128, 116 p.Serial Issue

Prodromal Psychosis: Diagnosis and TreatmentFUSAR-POLI, Paolo.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, issn 1381-6128, 278 p.Serial Issue

Predictive power of attenuated psychosis syndrome: Is it really low? The case of mild cognitive impairmentFUSAR-POLI, Paolo; BORGWARDT, Stefan.Schizophrenia research. 2012, Vol 135, Num 1-3, pp 192-193, issn 0920-9964, 2 p.Article

Eicosapentaenoic Acid Interventions in Schizophrenia: Meta-Analysis of Randomized, Placebo-Controlled StudiesFUSAR-POLI, Paolo; BERGER, Gregor.Journal of clinical psychopharmacology. 2012, Vol 32, Num 2, pp 179-185, issn 0271-0749, 7 p.Article

Abnormal Bodily Experiences May be a Marker of Early Schizophrenia?STANGHELLINI, Giovanni; BALLERINI, Massimo; FUSAR POLI, Paolo et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 392-398, issn 1381-6128, 7 p.Article

Neurophysiological Alterations in the Prepsychotic PhasesCROSSLEY, Nicolas A; CONSTANTE, Miguel; FUSAR-POLI, Paolo et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 479-485, issn 1381-6128, 7 p.Article

Neuroimaging and Resilience Factors - Staging of the At-risk Mental State?SMIESKOVA, Renata; FUSAR-POLI, Paolo; RIECHER-RÖSSLER, Anita et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 416-421, issn 1381-6128, 6 p.Article

The Relationship of Developmental Changes in White Matter to the Onset of PsychosisKARLSGODT, Katherine H; JACOBSON, Sarah C; SEAL, Marc et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 422-433, issn 1381-6128, 12 p.Article

Biochemical Markers of Impending PsychosisEMANUELE, Enzo; MARTINELLI, Valentina; ABBIATI, Vera et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 505-509, issn 1381-6128, 5 p.Article

Immigration, Social Environment and Onset of Psychotic DisordersBOURQUE, François; DER VEN, Elsje Van; FUSAR-POLI, Paolo et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 518-526, issn 1381-6128, 9 p.Article

Episodic Memory Dysfunction in Individuals at High-Risk of Psychosis: A Systematic Review of Neuropsychological and Neurofunctional StudiesVALLI, Isabel; TOGNIN, Stefania; FUSAR-POLI, Paolo et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 443-458, issn 1381-6128, 16 p.Article

The Ultra High Risk Approach to Define Psychosis RiskYUNG, Alison R; FUSAR-POLI, Paolo; NELSON, Barnaby et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 346-350, issn 1381-6128, 5 p.Article

Glutamate and Psychosis RiskEGERTON, Alice; FUSAR-POLI, Paolo; STONE, James M et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 466-478, issn 1381-6128, 13 p.Article

Cognitive Remediation in the Early Course of Schizophrenia: A Critical ReviewBARLATI, Stefano; DE PERI, Luca; DESTE, Giacomo et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 534-541, issn 1381-6128, 8 p.Article

Striatal Presynaptic Dopamine in Schizophrenia, Part I: Meta-Analysis of Dopamine Active Transporter (DAT) DensityFUSAR-POLI, Paolo; MEYER-LINDENBERG, Andreas.Schizophrenia bulletin. 2013, Vol 39, Num 1, pp 22-32, issn 0586-7614, 11 p.Article

What do ERPs and ERFs Reveal About the Effect of Antipsychotic Treatment on Cognition in Schizophrenia?KOROSTENSKAJA, M; KÄHKÖNEN, S.Current pharmaceutical design (Print). 2009, Vol 15, Num 22, pp 2573-2593, issn 1381-6128, 21 p.Article

Striatal Presynaptic Dopamine in Schizophrenia, Part II: Meta-Analysis of [¹⁸F/¹¹C]-DOPA PET StudiesFUSAR-POLI, Paolo; MEYER-LINDENBERG, Andreas.Schizophrenia bulletin. 2013, Vol 39, Num 1, pp 33-42, issn 0586-7614, 10 p.Article

The Phenomenology and Neurobiology of Delusion Formation During Psychosis Onset: Jaspers, Truman Symptoms, and Aberrant Salience : One Century of Allgemeine Psychopathologie (1913 to 2013) by Karl JaspersMISHARA, Aaron L; FUSAR-POLI, Paolo.Schizophrenia bulletin. 2013, Vol 39, Num 2, pp 278-286, issn 0586-7614, 9 p.Article

Psychoeducation in Subjects at Elevated Risk for Psychosis - A Critical ReviewHAUSER, Marta; JUCKEL, Georg.Current pharmaceutical design (Print). 2012, Vol 18, Num 4, pp 566-569, issn 1381-6128, 4 p.Article

Co-occurring mental and substance abuse disorders: A review on the potential predictors and clinical outcomesNAJT, Pablo; FUSAR-POLI, Paolo; BRAMBILLA, Paolo et al.Psychiatry research (Print). 2011, Vol 186, Num 2-3, pp 159-164, issn 0165-1781, 6 p.Article

Gray matters! - Mapping the transition to psychosisBORGWARDT, Stefan; MCGUIRE, Philip; FUSAR-POLI, Paolo et al.Schizophrenia research. 2011, Vol 133, Num 1-3, pp 63-67, issn 0920-9964, 5 p.Article